Supplement
Lutein
Half of the eye formula that earned its place, for people who already have macular degeneration.
Lutein is a yellow pigment (a xanthophyll carotenoid) concentrated in the macula, where it filters blue light and quenches oxidation. We grade Lutein B- on evidence and B- for worth-it at about $8-15 per month.
Evidence
Worth it
Typical cost: $8-15/month
What it does
Lutein is a yellow pigment (a xanthophyll carotenoid) concentrated in the macula, where it filters blue light and quenches oxidation. The body cannot make it; diet or supplements supply it. It is almost always sold and studied with its sibling pigment zeaxanthin, and the pair's evidence lives in the AREDS2 trial program for age-related macular degeneration (AMD).
What the research says
As part of the AREDS2 formula, slows progression of intermediate age-related macular degeneration
Evidence: moderate. AREDS2 (2013; 4,203 people with AMD) tested lutein 10 mg + zeaxanthin 2 mg: the primary comparison missed significance overall, but secondary analyses favored the pair over the original beta-carotene formula (HR 0.82 for progression), with the clearest benefit in people whose diets were lowest in these nutrients (HR about 0.74). The 10-year follow-up (Chew 2022) strengthened the case: HR 0.85 for progression to late AMD versus the beta-carotene formula, with no lung-cancer signal. This is treatment territory for people who already have AMD, not prevention for healthy eyes.
Raises macular pigment and may help glare and contrast in small studies
Evidence: emerging. Supplementation reliably increases macular pigment optical density, and small trials report improvements in glare disability, contrast sensitivity, and processing speed. Surrogate and small-study evidence; no trial shows lutein preventing AMD or eye disease in people without it.
No demonstrated benefit for cataracts
Evidence: moderate. AREDS2 tested it directly: lutein and zeaxanthin did not reduce cataract surgery or progression. The claim persists on labels anyway.
A narrow, genuine, establishment-grade use. The AREDS2 program is the largest eye-nutrition trial ever run, and over ten years the lutein-zeaxanthin substitution beat the beta-carotene formula it replaced while avoiding that formula's lung-cancer problem in smokers. The evidence is secondary-analysis-shaped in the parent trial and applies to people with existing macular degeneration, which caps the grade at B-: a real recommendation, for a specific population, with nothing proven for the general supplement buyer.
The week's longevity and biohacking news.
This grade for Lutein rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.
Is it worth it?
Evidence (B-) clears the leaderboard floor, and the worth-it grade is the derived value at this price: about $11 a month at the studied dose. Derived from the October 2026 worth-it model.
Typical cost
$8-15/month
Common form, not a brand recommendation
Dosage context established
The studied dose is 10 mg of lutein with 2 mg of zeaxanthin daily, the AREDS2 formula ratio, taken with food containing fat (these are fat-soluble pigments). Dietary intake in Western diets runs 1 to 2 mg/day combined; kale, spinach, and egg yolks are the meaningful food sources. Eye formulas that include lutein at 20 mg are exceeding the studied dose without a studied reason.
Worth-it leaderboard
Lutein sits outside the worth-it top 20.
Lutein sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Excellent safety record in trials up to a decade: the notable effect at high intakes is harmless skin yellowing (carotenodermia). Critically, unlike the beta-carotene it replaced in eye formulas, lutein showed no increased lung cancer risk in current or former smokers in the AREDS2 follow-up, which is a main reason eye specialists now prefer it. No significant drug interactions are documented.
Longevity Lab Report
Lutein news. Graded when it happens.
The grade on this page stays free. The email carries the news on lutein: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded with its pair partner zeaxanthin from the AREDS2 trial and its 10-year follow-up. The benefit is specific: progression of existing intermediate macular degeneration, strongest in people with low dietary intake. Prevention claims for healthy eyes are not supported and the record says so.
- 2026-10-23|Listed under longevity for its role in preserving vision in aging eyes; the library has no eye-health goal, and the record itself carries the population limits.